Progestin-only contraceptives: Effects on weight

Cochrane Database of Systematic Reviews

Volumn 2016, Issue 8, 2016, Pages

  Lopez, Laureen M ^a   Ramesh, Shanthi ^b   Chen, Mario ^a   Edelman, Alison ^c   Otterness, Conrad ^d   Trussell, James ^e   Helmerhorst, Frans M ^f  

^a FAMILY HEALTH INTERNATIONAL   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d Tak   (Thailand)

^e PRINCETON UNIVERSITY   (United States)

^f LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

GESTAGEN; INJECTABLE CONTRACEPTIVE AGENT; MEDROXYPROGESTERONE ACETATE; DRUG IMPLANT; LEVONORGESTREL; ORAL CONTRACEPTIVE AGENT;

BODY COMPOSITION; CONTRACEPTION; CONTRACEPTIVE BEHAVIOR; COPPER INTRAUTERINE DEVICE; HUMAN; LEVONORGESTREL RELEASING INTRAUTERINE SYSTEM; ORAL CONTRACEPTION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; WEIGHT CHANGE; WEIGHT GAIN; WEIGHT REDUCTION; ADOLESCENT; ADULT; BODY WEIGHT; DRUG EFFECTS; DRUG IMPLANT; FEMALE; INTRAUTERINE CONTRACEPTIVE DEVICE; PROSPECTIVE STUDY; RETROSPECTIVE STUDY;

ADOLESCENT; ADULT; BODY COMPOSITION; BODY WEIGHT; CONTRACEPTIVES, ORAL, HORMONAL; DRUG IMPLANTS; FEMALE; HUMANS; INTRAUTERINE DEVICES, MEDICATED; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE; PROGESTINS; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; WEIGHT GAIN;

EID: 84983591324     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD008815.pub4     Document Type: Review

References (112)

1. Ball MJ, Ashwell E, Gillmer MD. Progestagen-only oral contraceptives: comparison of the metabolic effects of levonorgestrel and norethisterone. Contraception 1991;44(3):223-33.
2. Bonny AE, Secic M, Cromer BA. A longitudinal comparison of body composition changes in adolescent girls receiving hormonal contraception. Journal of Adolescent Health 2009;45(4):423-5.
3. Castle WM, Sapire KE, Howard KA. Efficacy and acceptability of injectable medroxyprogesterone: a comparison of 3-monthly and 6-monthly regimens. South African Medical Journal 1978; Vol. 53, issue 21:842-5.
4. Dal'Ava N, Bahamondes L, Bahamondes MV, de Oliveira Santos A, Monteiro I. Body weight and composition in users of levonorgestrel-releasing intrauterine system. Contraception 2012;86(4):350-3.
5. Dal'Ava N, Bahamondes L, Bahamondes MV, Bottura BF, Monteiro I. Body weight and body composition of depot medroxyprogesterone acetate users. Contraception 2014;90(2):182-7.
6. Cursino K, Sider M, Pavin EJ, Dos Santos PN, Bahamondes L, Zantut-Wittmann DE, et al. Insulin resistance parameters in users of the injectable contraceptive depot medroxyprogesterone acetate during one year of use. European Journal of Contraception and Reproductive Health Care 2015;21(1):1-8.
7. Dos Santos PdeNS, Modesto WO, Dal'Ava N, Bahamondes M, Pavin E, Fernades A. Body composition and weight gain in new users of the three-monthly injectable contraceptive, depot-medroxyprogesterone acetate, after 12 months of follow-up. European Journal of Contraception and Reproductive Health Care 2014;19(6):432-38.
8. Modesto W, Bahamondes MV, Silva dos Santos P, Fernandes A, Dal'Ava N, Bahamondes L. Exploratory study of the effect of lifestyle counselling on bone mineral density and body composition in users of the contraceptive depot-medroxyprogesterone acetate. European Journal of Contraception and Reproductive Health Care 2014;19(4):244-9.
9. Espey E, Steinhart J, Ogburn T, Qualls C. Depo-provera associated with weight gain in Navajo women. Contraception. 2000/12/05 2000; Vol. 62, issue 2:55-8.
10. Modesto W, dos Santos PdeNS, Correia VM, Borges L, Bahamondes L. Weight variation in users of depot-medroxyprogesterone acetate, the levonorgestrel-releasing intrauterine system and a copper intrauterine device for up to ten years of use. European Journal of Contraception and Reproductive Health Care 2015;20(1):57-63.
11. Moore LL, Valuck R, McDougall C, Fink W. A comparative study of one-year weight gain among users of medroxyprogesterone acetate, levonorgestrel implants, and oral contraceptives. Contraception. 1995/10/01 1995; Vol. 52, issue 4:215-9.
12. Napolitano A, Zanin R, Palma F, Romani C, Grandi G, Di Carlo C, et al. Body composition and resting metabolic rate of perimenopausal women using continuous progestogen contraception. European Journal of Contraception and Reproductive Health Care 2015 Aug 25 [Epub ahead of print]:1-8.
13. Nyirati CM, Habash DL, Shaffer E. Weight and body fat changes in postpartum depot-medroxyprogesterone acetate users. Contraception 2013;88(1):169-76.
14. Pantoja M, Medeiros T, Baccarin MC, Morais S, Fernandes AM. Variation of weight among users of the contraceptive with depot-medroxyprogesterone acetate according to body mass index in a six-year follow-up. Revista Brasileira de Ginecologia e Obstetricia 2009; Vol. 31, issue 8:380-4.
15. Pantoja M, Medeiros T, Baccarin MC, Morais SS, Bahamondes L, Fernandes AM. Variations in body mass index of users of depot-medroxyprogesterone acetate as a contraceptive. Contraception 2010;81(2):107-11.
16. Salem HT, Abdullah KA, Shaaban MM. Norplant and lactation. The Norplant subdermal contraceptive system. Proceedings of the Symposium on Longterm Subdermal Contraceptive Implants; 1984 February 23-24. Assuit, Egypt: Assiut University, 1984:139-49.
17. Salem HT, Salah M, Aly MY, Thabet AI, Shaaban MM, Fathalla MF. Acceptability of injectable contraceptives in Assiut, Egypt. Contraception. 1988/12/01 1988; Vol. 38, issue 6:697-710.
18. Sivin I, Campodonico I, Kiriwat O, Holma P, Diaz S, Wan L, et al. The performance of levonorgestrel rod and Norplant contraceptive implants: a 5 year randomized study. Human Reproduction. 1999/01/14 1998; Vol. 13, issue 12:3371-8.
19. Sivin I, Viegas O, Campodonico I, Diaz S, Pavez M, Wan L, et al. Clinical performance of a new two-rod levonorgestrel contraceptive implant: a three-year randomized study with Norplant implants as controls. Contraception 1997;55(2):73-80.
20. Sule S, Shittu O. Weight changes in clients on hormonal contraceptives in Saria, Nigeria. African Journal of Reproductive Health 2005;9(2):92-100.
21. Taneepanichskul S, Reinprayoon D, Jaisamrarn U. Effects of DMPA on weight and blood pressure in long term acceptors. Contraception 1999;59(5):301-3.
22. Taneepanichskul S, Reinprayoon D, Khaosaad P. Comparative study of weight change between long-term DMPA and IUD acceptors. Contraception 1998;58(3):149-51.
23. Tankeyoon M, Dusitsin N, Poshyachinda V, Larsson-Cohn U. A study of glucose tolerance, serum transaminase and lipids in women using depot-medroxyprogesterone acetate and a combination-type oral contraceptive. Contraception 1976; Vol. 14, issue 2:199-214.
24. Tuchman LK, Huppert JS, Huang B, Slap GB. Adolescent use of the monthly contraceptive injection. Journal of Pediatric and Adolescent Gynecology 2005; Vol. 18, issue 4:255-60.
25. Vickery Z, Madden T, Zhao Q, Secura GM, Allsworth JE, Peipert JF. Weight change at 12 months in users of three progestin-only contraceptive methods. Contraception 2013;88(4):503-8.
26. Jain J, Jakimiuk AJ, Bode FR, Ross D, Kaunitz AM. Contraceptive efficacy and safety of DMPA-SC. Contraception 2004;70(4):269-75.
27. Westhoff C, Jain JK, Milsom I, Ray A. Changes in weight with depot medroxyprogesterone acetate subcutaneous injection 104 mg/0.65 mL. Contraception 2007;75(4):261-7.
28. World Health Organization. Multinational comparative clinical trial of long-acting injectable contraceptives: norethisterone enanthate given in two dosage regimens and depot-medroxyprogesterone acetate. A preliminary report. Contraception. 1982/01/01 1982; Vol. 25, issue 1:1-11.
29. World Health Organization. Multinational comparative clinical trial of long-acting injectable contraceptives: norethisterone enanthate given in two dosage regimens and depot-medroxyprogesterone acetate. Final report. Contraception. 1983/07/01 1983; Vol. 28, issue 1:1-20.
30. Agoestina T, Biben A. Use of Depo Provera in immediate post partum and lactating period at Dr Hasan Sadikin Hospital (1978). Report on file 10.
31. Bahamondes MV, Monteiro I, Castro S, Espejo-Arce X, Bahamondes L. Prospective study of the forearm bone mineral density of long-term users of the levonorgestrel-releasing intrauterine system. Human Reproduction 2010;25(5):1158-64.
32. Barsivala V, Virkar K, Kulkarni RD. Thyroid functions of women taking oral contraceptives. Contraception 1974; Vol. 9, issue 3:305-14.
33. Beksinska ME, Smit JA, Kleinschmidt I, Milford C, Farley TM. Prospective study of weight change in new adolescent users of DMPA, NET-EN, COCs, nonusers and discontinuers of hormonal contraception. Contraception 2010;81(1):30-4.
34. Berenson AB, Wiemann CM, Rickerr VI, McCombs SL. Contraceptive outcomes among adolescents prescribed Norplant implants versus oral contraceptives after one year of use. American Journal of Obstetrics and Gynecology 1997;176(3):586-92.
35. Berenson AB, Rahman M. Changes in weight, total fat, percent body fat, and central-to-peripheral fat ratio associated with injectable and oral contraceptive use. American Journal of Obstetrics and Gynecology. 2009/03/04 2009; Vol. 200, issue 3:329 e1-8.
36. Rahman M, Berenson AB. Self-perception of weight gain among multiethnic reproductive-age women. Journal of women's health (2002) 2012;21(3):340-6.
37. Bonny A, Camlin K, Harvey R, Islam KM, Debanne S. Prospective analysis of weight changes in adolescent females initiating depot medroxyprogesterone acetate (DMPA), oral contraceptive pills (OC), or no hormonal contraceptive method. Journal of Adolescent Health 2003;32(2):134.
38. Bonny AE, Secic M, Cromer BA. Relationship between weight and bone mineral density in adolescents on hormonal contraception. Journal of Pediatric and Adolescent Gynecology 2011;24(1):35-8.
39. Bonny AE, Ziegler J, Harvey R, Debanne SM, Secic M, Cromer BA. Weight gain in obese and nonobese adolescent girls initiating depot medroxyprogesterone, oral contraceptive pills, or no hormonal contraceptive method. Archives of Pediatrics & Adolescent Medicine. 2006/01/04 2006; Vol. 160, issue 1:40-5.
40. Bonny AE, Secic M, Cromer B. Early weight gain related to later weight gain in adolescents on depot medroxyprogesterone acetate. Obstetrics and Gynecology 2011;117:793-7.
41. Bonny AE, Lange HL, Hade EM, Kaufman B, Reed MD, Mesiano S. Serum adipocytokines and adipose weight gain: a pilot study in adolescent females initiating depot medroxyprogesterone acetate. Contraception 2015;92(4):298-300.
42. Casey PM, Long ME, Marnach ML, Fleming-Harvey J, Drozdowicz LB, Weaver AL. Association of body mass index with removal of etonogestrel subdermal implant. Contraception 2013;87(3):370-4.
43. Chen J, Wang XJ, Liang Y, Jin Q. [Clinic observation of a levonorgestrel-releasing intrauterine system inserted immediately after artificial abortion]. Zhonghua yi xue za zhi 2011;91(45):3176-8.
44. Clark MK, Dillon JS, Sowers M, Nichols S. Weight, fat mass, and central distribution of fat increase when women use depot-medroxyprogesterone acetate for contraception. International Journal of Obesity 2005; Vol. 29, issue 10:1252-8.
45. Clark MK, Sowers MR, Nichols S, Levy B. Bone mineral density changes over two years in first-time users of depot medroxyprogesterone acetate. Fertility and Sterility. 2004/12/14 2004; Vol. 82, issue 6:1580-6.
46. Costa ML, Cecatti JG, Krupa FG, Rehder PM, Sousa MH, Costa-Paiva L. Progestin-only contraception prevents bone loss in postpartum breastfeeding women. Contraception 2012;85(4):374-80.
47. Dahlberg K. Some effects of depo-medroxyprogesterone acetate (DMPA): observations in the nursing infant and in the long-term user. International Journal of Gynaecology and Obstetrics 1982; Vol. 20, issue 1:43-8.
48. El Mahgoub S. Body weight and cycle control of injectable contraceptives. Journal of Reproductive Medicine 1980;24(3):119-26.
49. Gallo MF, Legardy-Williams J, Hylton-Kong T, Rattray C, Kourtis AP, Jamieson DJ, et al. Association of Progestin Contraceptive Implant and Weight Gain. Obstetrics and Gynecology 2016;127(3):573-6.
50. Rattray C, Wiener J, Legardy-Williams J, Costenbader E, Pazol K, Medley-Singh N, et al. Effects of initiating a contraceptive implant on subsequent condom use: A randomized controlled trial. Contraception 2015;92(6):560-6.
51. Hall WD, Douglas MB, Blumenstein BA, Hatcher RA. Blood pressure and oral progestational agents. A prospective study of 119 black women. American Journal of Obstetrics and Gynecology 1980;136(3):344-8.
52. Havranek F, Tichy M, Divila F, Hejda V. Experience with the contraceptive effect of Depo-Provera, 300mg and 450mg administered at 6 month intervals [Zkusenosti s antikoncepcni ucinnosti Depo-Provery v davce 300mg a 450mg podanych v intervalech 6 mesicu]. Ceskoslovenska Gynekologie 1972; Vol. 37, issue 2:95-6.
53. Hernandez-Juarez J, Garcia-Latorre EA, Moreno-Hernandez M, Moran-Perez JF, Rodriguez-Escobedo MA, Cogque-Hernandez G, et al. Metabolic effects of the contraceptive skin patch and subdermal contraceptive implant in Mexican women: a prospective study. Reproductive Health 2014;11:33.
54. Kaunitz AM, Darney PD, Ross D, Wolter KD, Speroff L. Subcutaneous DMPA vs. intramuscular DMPA: a 2-year randomized study of contraceptive efficacy and bone mineral density. Contraception 2009;80(1):7-17.
55. Mangan SA, Larsen PG, Hudson S. Overweight teens at increased risk for weight gain while using depot medroxyprogesterone acetate. Journal of Pediatric and Adolescent Gynecology 2002; Vol. 15, issue 2:79-82.
56. Modesto W, Bahamondes MV, Bahamondes L. A randomized clinical trial of the effect of intensive versus non-intensive counselling on discontinuation rates due to bleeding disturbances of three long-acting reversible contraceptives. Human Reproduction 2014;29(7):1393-9.
57. Nault AM, Peipert JF, Zhao Q, Madden T, Secura GM. Validity of perceived weight gain in women using long-acting reversible contraception and depot medroxyprogesterone acetate. American Journal of Obstetrics and Gynecology 2013;208(1):48 e1-8.
58. Olsson SE, Odlind V, Johansson ED, Sivin I. Contraception with NORPLANT implants and NORPLANT-2 implants (two covered rods). Results from a comparative clinical study in Sweden. Contraception. 1988/01/01 1988; Vol. 37, issue 1:61-73.
59. Ortayli N, Bulut A, Sahin T, Sivin I. Immediate postabortal contraception with the levonorgestrel intrauterine device, Norplant, and traditional methods. Contraception 2001;63(6):309-14.
60. Risser WL, Gefter LR, Barratt MS, Risser JM. Weight change in adolescents who used hormonal contraception. Journal of Adolescent Health. 1999/07/13 1999; Vol. 24, issue 6:433-6.
61. Segall-Gutierrez P, Xiang A H, Watanabe R M, Trigo E, Stanczyk F Z, Liu X, et al. Deterioration in cardiometabolic risk markers in obese women during depot medroxyprogesterone acetate use. Contraception 2012;85(1):36-41.
62. Veisi F, Zangeneh M. Comparison of two different injectable contraceptive methods: depo-medroxy progesterone acetate (DMPA) and Cyclofem. Journal of Family and Reproductive Health 2013;7(3):109-13.
63. World Health Organization. Multinational comparative clinical evaluation of two long-acting injectable contraceptive steroids: norethisterone oenanthate and medroxyprogesterone acetate. 2. Bleeding patterns and side effects. Contraception. 1978/05/01 1978; Vol. 17, issue 5:395-406.
64. Yela DA, Monteiro IM, Bahamondes LG, Castillo SD, Bahamondes MV. Weight variation in users of the levonorgestrel-releasing intrauterine system, of the copper IUD and of medroxyprogesterone acetate in Brazil. Revista da Associacao Medica Brasileira 2006; Vol. 52, issue 1:32-6.
65. Zheng SR, Zheng HM, Qian SZ, Sang GW, Kaper RF. A randomized multicenter study comparing the efficacy and bleeding pattern of a single-rod (Implanon) and a six-capsule (Norplant) hormonal contraceptive implant. Contraception. 1999/11/05 1999; Vol. 60, issue 1:1-8.
66. Madden TE. Comparison of Body Composition & Weight Change in Users of Progestin-only Contraception During the First Year of Use (DEXA). clinicaltrials.gov/ct2/show/NCT01579773 (accessed 29 September 2015).
67. Schreiber CA. The Impact of Contraception on Postpartum Weight Loss (PPWL). clinicaltrials.gov/ct2/show/NCT01579773 (accessed 29 September 2015).
68. Bonny A. Drug Exposure and Depot Medroxyprogesterone Acetate (DMPA) in Adolescent Subjects. clinicaltrials.gov/ct2/show/NCT01461824 (accessed 29 September 2015).
69. Halpern V. Pharmacodynamics and Pharmacokinetics Study of Existing DMPA Contraceptive Methods. clinicaltrials.gov/ct2/show/NCT02456584 (accessed 16 October 2016).
70. American College of Obstetricians and Gynecologists. ACOG technical bulletin. Use of hormonal contraception in women with coexisting medical conditions. Washington, D.C.: American College of Obstetricians and Gynecologists, 2006.
71. Albright M, Rani S, Gavagan T. HelpDesk answers: do hormonal contraceptives lead to weight gain?. Journal of Family Practice 2015;64(6):371-2.
72. Bartz D, Goldberg AB. Injectable contraceptives. In: Hatcher RA, Trussell J, Nelson AL, Cates W, Kowal D, Policar MS editor(s). Contraceptive Technology. 20th Edition. New York: Ardent Media, Inc., 2011:209-36.
73. Basu T, Bao P, Lerner A, Anderson L, Page K, Stanczyk F, et al. The effect of depo medroxyprogesterone acetate (DMPA) on cerebral food motivation centers: a pilot study using functional magnetic resonance imaging. Contraception 2016 Apr 27 [Epub ahead of print]:1-7.
74. Bender NM, Segall-Gutierrez P, Najera SO, Stanczyk FZ, Montoro M, Mishell DR Jr. Effects of progestin-only long-acting contraception on metabolic markers in obese women. Contraception 2013;88(3):418-25.
75. Berenson AB, Odom SD, Breitkopf CR, Rahman M. Physiologic and psychologic symptoms associated with use of injectable contraception and 20 μg oral contraceptive pills. American Journal of Obstetrics and Gynecology. 2008/07/05 2008; Vol. 199, issue 4:351e1-12.
76. Bonny AE, Britto MT, Huang B, Succop P, Slap GB. Weight gain, adiposity, and eating behaviors among adolescent females on depot medroxyprogesterone acetate (DMPA). Journal of Pediatric and Adolescent Gynecology 2004;17(2):109-15.
77. Callegari LS, Nelson KM, Arterburn DE, Prager SW, Schiff MA, Schwarz EB. Factors associated with lack of effective contraception among obese women in the United States. Contraception 2014;90(3):265-71.
78. Centers for Disease Control and Prevention. Defining Overweight and Obesity. http://www.cdc.gov/obesity/adult/defining.html (accessed 19 December 2012).
79. Centers for Disease Control and Prevention. Summary Chart of U.S. Medical Eligibility Criteria for Contraceptive Use. www.cdc.gov/reproductivehealth/unintendedpregnancy/usmec.htm (accessed 1 March 2016).
80. Curtis KM, Ravi A, Gaffield ML. Progestogen-only contraceptive use in obese women. Contraception. 2009/09/16 2009; Vol. 80, issue 4:346-54.
81. Dickerson LM, Diaz VA, Jordon J, Davis E, Chirina S, Goddard JA, et al. Satisfaction, early removal, and side effects associated with long-acting reversible contraception. Family Medicine 2013;45(10):701-7.
82. Edelman AB, Cherala G, Munar MY, McInnis M, Stanczyk FZ, Jensen JT. Correcting oral contraceptive pharmacokinetic alterations due to obesity: a randomized controlled trial. Contraception 2014;90(5):550-6.
83. Flegal KM, Troiano RP. Changes in the distribution of body mass index of adults and children in the US population. International Journal of Obesity and Related Metabolic Disorders 2000;24(7):807-18.
84. Flegal KM, Carroll MD, Kit BK, Ogden CL. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. JAMA 2012;307(5):491-7.
85. Gallo MF, Lopez LM, Grimes DA, Schulz KF, Helmerhorst FM. Combination contraceptives: effects on weight. Cochrane Database of Systematic Reviews 2014, Issue 1. [DOI: 10.1002/14651858.CD003987.pub5]
86. Schünemann H, Brozek J, Guyatt G, Oxman A. GRADE Handbook [updated October 2013]. http://gdt.guidelinedevelopment.org/central_prod/_design/client/handbook/handbook.html (accessed 29 December 2015).
87. Grimes DA, Lopez LM, Manion C, Schulz KF. Cochrane systematic reviews of IUD trials: lessons learned. Contraception 2007;75(6 Suppl):S55-9.
88. Grimes DA, Lopez LM, O'Brien PA, Raymond EG. Progestin-only pills for contraception. Cochrane Database of Systematic Reviews 2013, Issue 11. [DOI: 10.1002/14651858.CD007541.pub3]
89. Guttmacher Institute. Contraceptive Use in the United States. October 2015. www.guttmacher.org/pubs/fb_contr_use.html (accessed 2 March 2016).
90. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org. John Wiley & Sons, Ltd, (accessed 1 October 2015).
91. Kavanaugh ML, Jerman J, Finer LB. Changes in use of long-acting reversible contraceptive methods among U.S. women, 2009-2012. Obstetrics and Gynecology 2015;126(5):917-27.
92. Kohn JE, Lopez PM, Simons HR. Weight and body mass index among female contraceptive clients. Contraception 2015;91(6):470-3.
93. Lange HL, Belury MA, Secic M, Thomas A, Bonny AE. Dietary intake and weight gain among adolescents on depot medroxyprogesterone acetate. Journal of Pediatric and Adolescent Gynecology 2015;28(3):139-43.
94. Le YC, Rahman M, Berenson AB. Early weight gain predicting later weight gain among depot medroxyprogesterone acetate users. Obstetrics and Gynecology 2009;114(2 Pt 1):279-84.
95. Lopez LM, Grimes DA, Chen-Mok M, Westhoff C, Edelman A, Helmerhorst FM. Hormonal contraceptives for contraception in overweight or obese women. Cochrane Database of Systematic Reviews 2013, Issue 4. [DOI: 10.1002/14651858.CD008452.pub3]
96. Merki-Feld GS, Skouby S, Serfaty D, Lech M, Bitzer J, Crosignani PG, et al. European society of contraception statement on contraception in obese women. European Journal of Contraception and Reproductive Health Care 2015;20(1):19-28.
97. Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of childhood and adult obesity in the united states, 2011-2012. JAMA 2014;311(8):806-14.
98. Paul C, Skegg DC, Williams S. Depot medroxyprogesterone acetate. Patterns of use and reasons for discontinuation. Contraception. 1997/12/31 1997; Vol. 56, issue 4:209-14.
99. Prentice AM. The emerging epidemic of obesity in developing countries. International Journal of Epidemiology 2006;35(1):93-9.
100. Raymond EG. Progestin-only pills. In: Hatcher RA, Trussell J, Nelson AL, Cates W Jr, Kowal D, Policar MS editor(s). Contraceptive technology. 20th Edition. New York: Ardent Media, Inc., 2011:237-47.
101. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
102. Robinson JA, Burke AE. Obesity and hormonal contraceptive efficacy. Womens Health 2013;9:453-66.
103. Silva-Filho AL, Lira J, Rocha AL, Ferreira MC, Lamaita RM, Candido EB, et al. Non-hormonal and hormonal intrauterine contraception: survey of patients' perceptions in four Latin American countries. European Journal of Contraception and Reproductive Health Care 2016 Feb 5 [Epub ahead of print]:1-7.
104. Sivin I. Risks and benefits, advantages and disadvantages of levonorgestrel-releasing contraceptive implants. Drug Safety. 2003/03/26 2003; Vol. 26, issue 5:303-35.
105. Steenland MW, Zapata LB, Brahmi D, Marchbanks PA, Curtis KM. Appropriate follow up to detect potential adverse events after initiation of select contraceptive methods: a systematic review. Contraception 2013;87(5):611-24.
106. Steward RG, Bateman LA, Slentz C, Stanczyk FZ, Price TM. The impact of short-term depot-medroxyprogesterone acetate treatment on resting metabolic rate. Contraception 2016;93(4):317-22.
107. Trussell J. Contraceptive failure in the United States. Contraception 2011;83(5):397-404.
108. United Nations, Department of Economic and Social Affairs. World Contraceptive Patterns 2015. www.un.org/en/development/desa/population/publications/ (accessed 23 February 2015).
109. WebMD Progestin-only hormonal methods (mini-pills, implants, and shots). http://www.webmd.com/sex/birth-control/progestin-only-hormonal-methods-mini-pills-shots (accessed 15 Jun 2010).
110. GA Wells, Shea B, O'Connell D, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. www.ohri.ca/programs/clinical_epidemiology/oxford.asp (accessed 6 October 2015).
111. World Health Organization, Department of Reproductive Healh. Medical eligibility criteria for contraceptive use. Fifth edition - Executive Summary, 2015. http://www.who.int/reproductivehealth/publications/family_planning/Ex-Summ-MEC-5/en/ (accessed 2 July 2015).
112. World Health Organization, Department of Reproductive Health. Medical eligibility criteria wheel for contraceptive use. 2015. http://www.who.int/reproductivehealth/publications/family_planning/Ex-Summ-MEC-5/en/ (accessed 2 July 2015).